drugset / Trial / NCT06471738
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .
Timeline
- Start
- 2024-07-10
- Primary completion
- 2026-12-30
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |